A Phase I, Open Label, Randomized, Four-Period Crossover Study to Evaluate the Effects of Calcium Carbonate 1200 mg and Ferrous Fumarate 324 mg on Pharmacokinetics of Dolutegravir 50 mg in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 01 Dec 2014
At a glance
- Drugs Dolutegravir (Primary) ; Calcium carbonate; Ferrous fumarate
- Indications HIV infections
- Focus Pharmacokinetics
- Sponsors ViiV Healthcare
- 01 Mar 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 Jan 2013 New trial record
- 01 Dec 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.